Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVONEST vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Emergency contraception (FDA-approved),Contraception (as a progestin-only pill or in combination with estrogen),Off-label: treatment of menorrhagia, endometriosis, and as a component of hormone replacement therapy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
400 mg orally once daily with food.
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Primarily hepatic via CYP3A4; undergoes reduction and conjugation; excreted in urine and feces.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Levonorgestrel is extensively bound to sex hormone-binding globulin (SHBG) and albumin; approximately 97-99% bound, with the free fraction being pharmacologically active.
98% bound to albumin
Apparent volume of distribution is about 1.8 L/kg, indicating extensive distribution into tissues beyond plasma water.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral bioavailability is approximately 100% due to minimal first-pass metabolism; levonorgestrel is completely absorbed after oral administration.
Oral: 85-90%; IM: 95-100%
No dosage adjustment required for any degree of renal impairment.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, no specific dose adjustment available; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Weight ≥ 75 kg: single dose of levonorgestrel 1.5 mg orally. Weight < 75 kg: single dose of 1.5 mg is also used, but efficacy may be reduced; consider alternative methods.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for postmenopausal women; no specific dose adjustment established for elderly.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
None.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Do not use as regular contraceptive if multiple doses are taken in one cycle,Ectopic pregnancy risk reduced but not eliminated,Menstrual irregularities,Rare cases of hepatic adenoma or thromboembolic events,Use with caution in patients with severe hepatic impairment or malabsorption syndromes
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Known or suspected pregnancy,Hypersensitivity to levonorgestrel or any component
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No clinically significant food interactions. Levonest releases levonorgestrel locally in the uterus, and systemic absorption is minimal. No dietary restrictions required.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
LEVONEST (levonorgestrel) is associated with minimal teratogenic risk if inadvertently used during pregnancy. First trimester: No increased risk of major malformations based on epidemiologic data. Second/third trimester: No known adverse fetal effects from occasional use; no evidence of fetotoxicity or teratogenicity from clinical studies. However, as a progestin-only contraceptive, it is not indicated during pregnancy.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Levonorgestrel is excreted into breast milk in small amounts (estimated infant dose <0.1% of maternal dose). M/P ratio not established. No adverse effects reported in breastfed infants with short-term use. The WHO considers it compatible with breastfeeding. Caution with prolonged use may reduce milk supply.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
No dosing adjustments are applicable as LEVONEST is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy do not require dose modifications because the drug should not be used during pregnancy.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Levonest (levonorgestrel-releasing intrauterine system) provides effective contraception for up to 5 years. It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. May reduce menstrual bleeding and dysmenorrhea. Expulsion risk is highest in first year, especially right after insertion. Check strings after each period. Contraindicated in acute pelvic inflammatory disease, postpartum endometritis, infected abortion, or untreated cervical infection.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Levonest is a small T-shaped device placed in your uterus that releases a hormone to prevent pregnancy for up to 5 years.,You may have irregular bleeding or spotting for the first 3-6 months, which typically decreases over time.,Check the strings at the end of your period each month to ensure the device is in place.,Do not use Levonest if you think you might be pregnant, have a current pelvic infection, or have certain uterine abnormalities.,Most women can use Levonest safely; serious complications are rare but include perforation, expulsion, and infection.,Seek medical attention if you experience severe abdominal pain, fever, heavy bleeding, or missing strings.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVONEST vs ADQUEY, answered by our medical review team.
LEVONEST is a Oral Contraceptive that works by Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVONEST and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVONEST is: One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVONEST and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVONEST is classified as Category C. LEVONEST (levonorgestrel) is associated with minimal teratogenic risk if inadvertently used during pregnancy. First trimester: No increased risk of major malformations based on epi. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.